<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2017//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_170101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">27027541</PMID>
        <DateCreated>
            <Year>2016</Year>
            <Month>08</Month>
            <Day>20</Day>
        </DateCreated>
        <DateRevised>
            <Year>2017</Year>
            <Month>02</Month>
            <Day>20</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1557-8992</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>26</Volume>
                    <Issue>6</Issue>
                    <PubDate>
                        <Year>2016</Year>
                        <Month>Aug</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of child and adolescent psychopharmacology</Title>
                <ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Neural Correlates of Symptom Improvement Following Stimulant Treatment in Adults with Attention-Deficit/Hyperactivity Disorder.</ArticleTitle>
            <Pagination>
                <MedlinePgn>527-36</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.1089/cap.2015.0243</ELocationID>
            <Abstract>
                <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The purposes of this study were to examine the impact of 3 weeks of amphetamine administration on intrinsic connectome-wide connectivity patterns in adults with attention-deficit/hyperactivity disorder (ADHD) and explore the association between stimulant-induced symptom improvement and functional connectivity alteration.</AbstractText>
                <AbstractText Label="METHODS" NlmCategory="METHODS">Participants included 19 adults (age 20-55 years) diagnosed with ADHD using the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR) criteria per the Adult Clinician Diagnostic Scale taking part in amphetamine trials. For each patient, two 6-minute resting-state functional magnetic resonance imaging (R-fMRI) scans were acquired at baseline and after treatment. A fully data-driven multivariate analytic approach (i.e., multivariate distance matrix regression [MDMR]) was applied to R-fMRI data to characterize the distributed pharmacological effects in the entire functional connectome. Clinical efficacy was assessed using ADHD rating scale with adult prompts and the Adult Self-Report Scale v1.1 Symptom Checklist. We linked stimulant-induced functional connectivity changes to symptom amelioration using Spearman's correlation.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Three weeks of administration of a stimulant significantly reduced ADHD symptoms. MDMR-based analyses on R-fMRI data highlighted the left dorsolateral prefrontal cortex (DLPFC, a key cognitive control region) and the medial prefrontal cortex (MPFC, the anterior core of default network) whose distributed patterns of functional connectivity across the entire brain were altered by psychostimulants. Follow-up intrinsic functional connectivity revealed that stimulants specifically decreased the positive functional connectivity between DLPFC-insula, DLPFC-anterior cingulate cortex, and MPFC-insula. Importantly, these functional connectivity changes are associated with symptom improvement.</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggested that ADHD is associated with increased functional integration or decreased functional segregation between core regions of cognitive control, default, and salience networks. The apparent normalization of intrinsic functional interaction in these circuits (i.e., increased functional segregation) may underlie the clinical benefits produced by 3 weeks of amphetamine treatment.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Yang</LastName>
                    <ForeName>Zhen</ForeName>
                    <Initials>Z</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Center for the Developing Brain, Child Mind Institute , New York, New York.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2 Nathan Kline Institute for Psychiatric Research , Orangeburg, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Kelly</LastName>
                    <ForeName>Clare</ForeName>
                    <Initials>C</Initials>
                    <AffiliationInfo>
                        <Affiliation>3 The Child Study Center at NYU Langone Medical Center , New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Castellanos</LastName>
                    <ForeName>Francisco X</ForeName>
                    <Initials>FX</Initials>
                    <AffiliationInfo>
                        <Affiliation>2 Nathan Kline Institute for Psychiatric Research , Orangeburg, New York.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>3 The Child Study Center at NYU Langone Medical Center , New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Leon</LastName>
                    <ForeName>Terry</ForeName>
                    <Initials>T</Initials>
                    <AffiliationInfo>
                        <Affiliation>4 Department of Psychiatry, NYU Langone School of Medicine , New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Milham</LastName>
                    <ForeName>Michael P</ForeName>
                    <Initials>MP</Initials>
                    <AffiliationInfo>
                        <Affiliation>1 Center for the Developing Brain, Child Mind Institute , New York, New York.</Affiliation>
                    </AffiliationInfo>
                    <AffiliationInfo>
                        <Affiliation>2 Nathan Kline Institute for Psychiatric Research , Orangeburg, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Adler</LastName>
                    <ForeName>Lenard A</ForeName>
                    <Initials>LA</Initials>
                    <AffiliationInfo>
                        <Affiliation>4 Department of Psychiatry, NYU Langone School of Medicine , New York, New York.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2016</Year>
                <Month>03</Month>
                <Day>30</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>United States</Country>
            <MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA>
            <NlmUniqueID>9105358</NlmUniqueID>
            <ISSNLinking>1044-5463</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <CommentsCorrectionsList>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2002 Oct;17(2):825-41</RefSource>
                <PMID Version="1">12377157</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>BMC Psychiatry. 2011 Nov 10;11:176</RefSource>
                <PMID Version="1">22074258</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 2011 Jun 15;69(12 ):e145-57</RefSource>
                <PMID Version="1">21550021</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Postgrad Med. 2011 Sep;123(5):71-9</RefSource>
                <PMID Version="1">21904088</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Front Syst Neurosci. 2013 Feb 04;6:80</RefSource>
                <PMID Version="1">23382713</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2013 Nov 1;81:213-21</RefSource>
                <PMID Version="1">23684862</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2007 Aug 1;37(1):90-101</RefSource>
                <PMID Version="1">17560126</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2014 Jun;93 Pt 1:74-94</RefSource>
                <PMID Version="1">24583255</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain Imaging Behav. 2016 Jun;10(2):548-58</RefSource>
                <PMID Version="1">26149196</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Atten Disord. 2017 Jan;21(2):149-157</RefSource>
                <PMID Version="1">23657761</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychiatry Neurosci. 2015 Jan;40(1):46-57</RefSource>
                <PMID Version="1">25266402</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2006 Nov;31(11):2376-83</RefSource>
                <PMID Version="1">16855530</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychiatry Res. 2014 Apr 30;222(1-2):75-83</RefSource>
                <PMID Version="1">24679996</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Arch Gen Psychiatry. 2008 Jan;65(1):102-14</RefSource>
                <PMID Version="1">18180434</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Psychiatry. 2004 Nov;161(11):1990-7</RefSource>
                <PMID Version="1">15514398</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychopathol Behav Assess. 2011 Dec;33(4):420-429</RefSource>
                <PMID Version="1">22228922</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neurosci Biobehav Rev. 2007;31(7):977-86</RefSource>
                <PMID Version="1">17445893</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychiatry Res. 2010 May 30;177(3):299-304</RefSource>
                <PMID Version="1">20452063</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2013 Sep;78:59-67</RefSource>
                <PMID Version="1">23603346</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Hum Brain Mapp. 2014 Nov;35(11):5379-88</RefSource>
                <PMID Version="1">24862742</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Eur Neuropsychopharmacol. 2013 Oct;23(10):1151-64</RefSource>
                <PMID Version="1">23165220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 2010 Jun;71(6):754-63</RefSource>
                <PMID Version="1">20051220</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropsychopharmacology. 2013 Jun;38(7):1287-95</RefSource>
                <PMID Version="1">23340519</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Expert Rev Neurother. 2014 May;14(5):519-38</RefSource>
                <PMID Version="1">24738703</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Brain. 2014 Sep;137(Pt 9):2423-8</RefSource>
                <PMID Version="1">24916335</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuroimage. 2011 Feb 1;54(3):2033-44</RefSource>
                <PMID Version="1">20851191</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Ann Clin Psychiatry. 2006 Jul-Sep;18(3):145-8</RefSource>
                <PMID Version="1">16923651</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Trends Cogn Sci. 2012 Jan;16(1):17-26</RefSource>
                <PMID Version="1">22169776</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychol Med. 2005 Feb;35(2):245-56</RefSource>
                <PMID Version="1">15841682</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Clin Psychiatry. 2013 Sep;74(9):902-17</RefSource>
                <PMID Version="1">24107764</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Magn Reson Med. 1996 Mar;35(3):346-55</RefSource>
                <PMID Version="1">8699946</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Neuropharmacology. 2009 Dec;57(7-8):640-52</RefSource>
                <PMID Version="1">19715709</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Psychiatr Res. 2011 Feb;45(2):150-5</RefSource>
                <PMID Version="1">20656298</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Acta Psychiatr Scand. 2012 Feb;125(2):147-56</RefSource>
                <PMID Version="1">22097933</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>J Child Psychol Psychiatry. 2007 Sep;48(9):899-913</RefSource>
                <PMID Version="1">17714375</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Biol Psychiatry. 2015 Nov 2;:</RefSource>
                <PMID Version="1">26805582</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Am J Psychiatry. 2012 Oct;169(10):1038-55</RefSource>
                <PMID Version="1">22983386</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>MMWR Morb Mortal Wkly Rep. 2010 Nov 12;59(44):1439-43</RefSource>
                <PMID Version="1">21063274</PMID>
            </CommentsCorrections>
            <CommentsCorrections RefType="Cites">
                <RefSource>Psychiatr Clin North Am. 2004 Jun;27(2):187-201</RefSource>
                <PMID Version="1">15063992</PMID>
            </CommentsCorrections>
        </CommentsCorrectionsList>
        <OtherID Source="NLM">PMC4991601 [Available on 08/01/17]</OtherID>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="pmc-release">
                <Year>2017</Year>
                <Month>08</Month>
                <Day>01</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>3</Month>
                <Day>31</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">27027541</ArticleId>
            <ArticleId IdType="doi">10.1089/cap.2015.0243</ArticleId>
            <ArticleId IdType="pmc">PMC4991601</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>
